Back to top
more

Eli Lilly (LLY)

(Delayed Data from NYSE)

$639.43 USD

639.43
6,903,276

+4.21 (0.66%)

Updated Aug 12, 2025 04:00 PM ET

After-Market: $645.00 +5.57 (0.87%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (89 out of 245)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Swarup Gupta headshot

5 Tiny Biotech Stocks With Superb Growth Potential

by Swarup Gupta

A spurt in deal-making has boosted the sector this year which retains the ability to provide outsized gains.

Mark Vickery headshot

Top Stock Reports for Disney, Eli Lilly & U.S. Bancorp

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Disney (DIS), Eli Lilly (LLY) and U.S. Bancorp (USB).

Zacks Equity Research

Lilly to Begin Exchange Offer for Sale of Balance Elanco Stake

by Zacks Equity Research

Eli Lilly (LLY) to initiate an exchange offer for shareholders to divest its remaining ownership interest in Elanco

Zacks Equity Research

Teva (TEVA) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

While pricing erosion in U.S. generics market and lower sales of Copaxone are expected to hurt sales at Teva (TEVA), cost savings from an aggressive restructuring plan will support the bottom line.

Zacks Equity Research

Incyte Down as FDA Extends Review Period of Jakafi for GVHD

by Zacks Equity Research

The FDA extends the review period of Incyte's (INCY) sNDA for the label expansion of Jakafi for the treatment of acute GVHD.

Zacks Equity Research

Pharma Stock Roundup: Q4 Earnings at MRK, LLY, CHMP Nod for Several Drugs

by Zacks Equity Research

Merck (MRK) and Lilly (LLY) report Q4 results. CHMP gives nod to several drugs.

Zacks Equity Research

Stock Market News For Feb 7, 2019

by Zacks Equity Research

U.S. stocks closed lower on Wednesday following disappointing earnings results from videogame companies.

Zacks Equity Research

Sanofi (SNY) Q4 Earnings Top, Genzyme Unit Drives Sales Growth

by Zacks Equity Research

Sanofi (SNY) beat estimates for earnings and missed the same for sales in the fourth quarter. The Specialty Care unit drove top-line growth.

Zacks Equity Research

Lilly (LLY) Lags Q4 Earnings, Lowers 2019 View, Stock Down

by Zacks Equity Research

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued guidance for earnings and sales. Stock drops in pre-market trading.

Zacks Equity Research

Eli Lilly (LLY) Lags Q4 Earnings, Tops Sales, Cuts 2019 View

by Zacks Equity Research

Eli Lilly (LLY) misses estimates for earnings but beats the same for sales. The company lowers its previously issued outlook for earnings and sales. Stock drops in pre-market trading.

Zacks Equity Research

Sanofi's Myeloma Candidate Meets Goal in Phase III Study

by Zacks Equity Research

Sanofi's (SNY) late-stage candidate, isatuximab, achieves the primary endpoint in a pivotal study by prolonging progression free survival in patients with relapsed/refractory multiple myeloma.

Zacks Equity Research

Merck's Keytruda Clinches CHMP Nod for Difficult Lung Cancer

by Zacks Equity Research

Merck (MRK) secures a positive verdict from the Committee for Medicinal Products for Human Use to approve Keytruda's combo therapy for first-line treatment of a difficult lung cancer population.

Zacks Equity Research

Roche Submits sBLA to FDA for Label Expansion of Kadcyla

by Zacks Equity Research

Roche (RHHBY) submits sBLA for Kadcyla to the FDA for adjuvant treatment of patients with HER2-positive early breast cancer with residual disease after neoadjuvant treatment.

Zacks Equity Research

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

by Zacks Equity Research

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

Zacks Equity Research

Lilly/Incyte's Olumiant Meets Endpoint in Eczema Studies

by Zacks Equity Research

Eli Lilly and Company (LLY) and partner Incyte's Olumiant meets primary endpoint in two phase III studies evaluating it for moderate-to-severe atopic dermatitis.

Zacks Equity Research

Teva Gains Positive CHMP Opinion for Migraine Drug Ajovy

by Zacks Equity Research

Teva (TEVA) receives positive opinion from the Committee for Medicinal Products for Human Use (CHMP), advocating a marketing approval for its new migraine medicine, Ajovy.

Zacks Equity Research

Novo Nordisk (NVO) Q4 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Novo Nordisk (NVO) fourth-quarter 2018 results mainly benefit from strong performance by Ozempic.

Zacks Equity Research

Lilly (LLY) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Lilly (LLY) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Pharma Stock Roundup: Q4 Earnings, Pipeline Updates at PFE, RHHBY

by Zacks Equity Research

Pfizer (PFE), Allergan (AGN), AbbVie (ABBV) and Novartis (NVS) report Q4 results.

Zacks Equity Research

J&J's Erleada Meets Both Primary Endpoints in Late-Stage Study

by Zacks Equity Research

Johnson & Johnson's (JNJ) Erleada improves survival in metastatic castration-sensitive prostate cancer study.

Zacks Equity Research

Eli Lilly (LLY) Q4 Earnings Coming Up: What's in the Cards?

by Zacks Equity Research

Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are performing well. Let's see if these along with its older products lead the company to an earnings beat.

Zacks Equity Research

Lilly/Pfizer's Osteoarthritis Pain Drug Succeeds in 2nd Study

by Zacks Equity Research

Eli Lilly (LLY) and Pfizer announce that their investigational pain candidate, tanezumab, achieves significant reduction in pain in osteoarthritis patients in second late-stage study.

Sweta Killa headshot

Should You Invest in the VanEck Vectors Pharmaceutical ETF (PPH)?

by Sweta Killa

Sector ETF report for PPH

Zacks Equity Research

Dr. Reddy's (RDY) to Report Q3 Earnings: What's in Store?

by Zacks Equity Research

Dr. Reddy's has launched few generics which should add to revenues of the company when the company releases its third-quarter fiscal 2019 results.

Zacks Equity Research

Allergan Hikes Quarterly Dividend by 2.8% Ahead of Q4 Results

by Zacks Equity Research

Allergan (AGN) approves a cash dividend of 74 cents for 2019, a 2.8% raise from the previous payout of 72 cents.